Status:
COMPLETED
Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19
Lead Sponsor:
Kerecis Ltd.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). A double blind clinical trial will be conducted to evaluate the Device against placebo in ...
Eligibility Criteria
Inclusion
- ≥18 years of age
- Positive for SARS-CoV-2 infection
- Has symptoms of upper respiratory infection
- Willing to participate in the clinical trial and gives consent
- Is not pregnant, nor actively trying to conceive a child.
Exclusion
- Under 18 years of age
- Negative for SARS-CoV-2 infection
- Severe symptoms of infection
- Symptoms involving the entire respiratory system, including Pneumonia
- Requires hospitalisation prior to study start
- Asymptomatic
- Pregnant or actively trying to conceive a child
- Other comorbidities that would prevent administration of the device
- Requirement to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
- Patients with known allergies to Neem or Hypericum oil
- Patients with asthma
Key Trial Info
Start Date :
September 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2020
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04357990
Start Date
September 4 2020
End Date
October 30 2020
Last Update
July 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Hospital of Iceland (Landspítali)
Reykjavik, Iceland, 101